IVUS plaque regression with high doses of statins

Original title: Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Reference: Räber L et al. Eur Heart J. 2015 Feb 21;36(8):490-500.

The long-term effect of intensive statin therapy on coronary atherosclerosis in patients admitted pursuing an ST segment elevation myocardial infarction is unknown. The aim of this study was to quantify the impact of high doses of statins in the volume and composition of plaques in the arteries unrelated to the infarction.Between 2009 and 2011, 103 patients admitted pursuing ST segment elevation myocardial infarction were performed a coronary intravascular ultrasound (IVUS) on the two arteries not responsibleof infarction after successful primary angioplasty to the guilty artery.

These patients were treated with 40 mg of rosuvastatin for 13 months and thereafter a serial analysis was performed with IVUS. The primary end point was the percentage change in plaque volume by IVUS.After 13 months a significant decrease in LDL and a significant increase in the value of HDL were observed. Reduced plaque volume in arteries unrelated to myocardial infarction 0.9% (IC 95% -1.56 to -0.25, p = 0.007).In 74% of the population regression of plates at least in one artery not infarct-relatedwas observed.The necrotic core showed no change (-0.05%; CI 95% -1.05 to 0.96%, p = 0.93) as well as the number of plates with thin fibrous cap (124 versus 116, p = 0.15).

Conclusion

After 13 months of high-dose rosuvastatin it was observed by IVUS a regression of plaques in the arteries unrelated to myocardial infarction.

Editorial comment

While the regression existed and was significant, this did not reach 1% of the volume of original plaque and this after more than a year of rosuvastatin 40 mg (dose that not all patients tolerate). The anatomical regression is significant but low impact on functional compromise that an injury can have.

SOLACI

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...